bluebird bio Inc (LTS:0HOH)
$ 0.3637 0 (0%) Market Cap: 73.46 Mil Enterprise Value: 371.21 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 29/100

bluebird bio Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 15, 2020 / 05:15PM GMT
Release Date Price: $57.04
Matthew Kelsey Harrison;Nick Leschly
Morgan Stanley, Research Division - Executive Director;bluebird bio, Inc. - President, CEO & Director

Everybody, thanks for joining us for the next session. I'm Matthew Harrison, I'm one of the biotech analysts here at Morgan Stanley. Pleased to have Bluebird with me for the next session.

Quickly before we get started, I need to read a disclaimer. Please note that this webcast is for Morgan Stanley clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you are a member of the press, please disconnect and reach out separately.

For important disclosures, please see the Morgan Stanley research disclosures website at morganstanley.com/research disclosures. And if you have any questions, please reach out to your Morgan Stanley representative.

And with that, very pleased to have Nick Leschly, the CEO of Bluebird, as well as Philip Gregory. And Nick, I'm going to turn it over to you to start off, to give us some opening comments, and then we'll jump into Q&A.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot